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Background: One of the malignant tumors among head and neck cancers is nasopharyngeal carcinoma. Many studies consider 
human papilloma virus (HPV) as a cause for nasopharyngeal carcinoma. Methods: 41 paraffin-wax-embedded block samples were 
examined to detect HPV DNA and its subtype’s presence by polymerase chain reaction. The recurrence, prognosis and survival 
were evaluated for an average of 48 months. Results: HPV DNA was positive in 9 patients (22%). The overall recurrence rate was 
75% in HPV negative patients and 11% in HPV positive ones. The mortality rate in HPV negative and positive patients was 37.5% 
and 0%, respectively. Conclusion: HPV type 18 and 16 were the most common subtypes. Also, it can be implied that patients which 
are HPV positive had better prognosis and also less recurrence.
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The overall incidence of nasopharyngeal carci-
noma (NPC) is 1/100000 [1]. NPC is a common cancer 
in Southeast Asia [2] but a rare disease in the United 
States [3, 4]. Etiologically, NPC is induced by diffe rent 
factors, including infections (e.g., EBV and human 
papilloma virus — HPV), environmental factors, and 
genetics. HPV DNA expression has been reported 
to be between 9% and 51% in NPC [5, 6]. HPV has 
been also detected in 73% of patients with tonsilar 
cancers in the United States [4]. In the case of Mo-
roccan patients, HPV prevalence in NPC is 34% [7].
The World Health Organization (WHO) has classified 
NPC histologically into 3 types: type I (keratinizing squa-
mous cell carcinoma (SCC)), type II (non-keratinizing 
SCC), and type III (undifferentiated carcinoma) [1, 4]. 
In this study, we searched for the presence of HPV DNA 
types (18, 16, 11 and 6) in NPC by PCR in paraffin-wax-
embedded blocks to find out if there is any correlation 
between this presence and pathologic features, progno-
sis, recurrence and survival of the patients.
All patients underwent biopsy in the Otolaryngo-
logy Department of Shahid Sadoughi General Hospital 
in Yazd between 1995 and 2007. The total number 
of 41 patients was diagnosed with NPC and paraffin-
wax-embedded blocks were collected. The clinical 
presentation of tumors, including palpable lymph node, 
nasal obstruction, epistaxis, and hearing loss were col-
lected from admission files. On the basis of hematoxy-
line and eosin (H + E) staining, these samples were clas-
sified according to the WHO classification. Also, by using 
H + E staining, we were enabled to identify tumor rich 
area and core samples were taken from them. To pre-
pare samples for DNA isolation, deparaffinization was 
done with Xylene and DNA was retrieved by the DNAsy 
Blood & Tissue QIAGEN kit (Valencia, CA, USA).
HPV kit (GENKAM, Germany) was used for per-
forming PCR. Each sample was subjected to PCR reac-
tions using GP5+/GP6+ primer sets and type-specific 
primers for HPV6, 11, 16 and 18. The final 50 μl PCR 
mixture contained 10-μl sample, 25-μl PCR Master 
Mix Promega, mixed with 3 mM MgCl2, and 20 pmol 
of each primer. Cycling profile was done with these 
amplifications settings: 5 min incubation at 94 °C and 
1 min denaturation for 40 cycles at 95 °C, 1 min an-
nealing and elongation at 55 °C and 72 °C, respectively. 
Final extension of 10 min at 72 °C was performed after 
the last cycle [8].
To evaluate NPC recurrence, nasopharyngoscopy, 
CT or MRI was used when the new symptoms of NPC 
were present at least 6 months after the treatment.
The treatment plan was either radiotherapy or chemo-
radiotherapy. Regardless of pathology report radiothera-
py alone was considered only for stage T1N0 (T1: tumor 
was confined to nasopharynx). Although none of our 
patients were classified in this group, all of them were 
treated with chemoradiotherapy according to the follow-
ing protocol: 160 mg/m2 of cisplatin on day 1, day 22 and 
day 44 of course of the protocol; and they also underwent 
a radiothe rapy in which 7000 cGy (cumulative dose) was 
given. These pati ents have received 80 mg/m2 of cisplatin 
and 1000 mg/m2 of 5-fluorouracil per day by continuous 
infusion days 1–4, after a rest of 28 days. The procedures 
of the study were approved ethically by Shahid Sadoughi 
University Ethics committee. The data were analyzed 
using SPSS statistical software (Chicago, Illinois, USA).
41 paraffin-wax-embedded blocks were collected from 
enrolled patients (34 men and 7 women) and assessed 
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by PCR methods. The average age at the time of biopsy 
was 26 years with a range of 14 to 82 years. The average 
mean follow-up time was 48 months (13–150).
According to the WHO classification, 24 cases 
(58.6%) were classified as WHO type III, 14 (34.1%) 
as WHO type II, and 3 cases (7.3%) as WHO type I (Table).
48% of the NPC cases were presented with palpa-
ble cervical lymph nodes, 34% with nasal obstructions, 
10% with epistaxis, and 8% with hearing loss. HPV 
was positive in 9 of the 41 cases (22%). Among those 
samples which were HPV-positive, 5 (55.6%) cases 
were HPV type 18; 3 (33.3%) HPV type 16; 1 (11.1%) 
HPV type 6 and none of the samples were positive for 
HPV DNA type 11 (Table).
Table. WHO histological classifications of NPC and frequency presence 
of HPV DNA types (18, 16, 11 and 6) in this study
WHO classifications HPV 
nega-
tive
HPV positive (22%)
Type I Type II Type III Type 18
Type
16
Type
11
Type
6
Patient
(%)
3
(7.3)
14
(34.1)
24
(58.6)
32
(78)
5
(55.6)
3
(33.3)
0
(0)
1
(11.1)
The overall recurrence rate was 75% (24 of 32) 
in HPV-negative patients and 11.1% (1 from 9) in HPV-
positive ones. The overall mortality rate was 37.5% 
(12 of 32) in HPV-negative patients and zero in HPV-
positive patients (0 of 9).
HPV is a double stranded DNA virus, and several 
studies have indicated that there is a correlation be-
tween HPV infection and head and neck SCC (HN-
SCC) [2]. Also, different studies have reported that 
the expression of HPV DNA among patients with NPC 
has a range about 9 to 51% [5, 6]. Most studies have 
been conducted in Southeast Asia [2]. In Southern 
India, Krishna et al. reported that HPV was positive 
in 38.8% of 36 patients with NPC [9]. Another study 
of 30 patients with NPC showed that 7 patients were 
HPV-positive [1]. Mirzamani et al. [2] performed 
an in situ hybridization investigation for the detection 
of HPV DNA in NPC patients inside Iran and found 
20% of the samples were HPV-positive. In the current 
study, we found out the presence of HPV DNA in 22% 
of NPC tissue blocks. Considering HPV genotypes, 
HPV 18 (55.6%) and HPV 16 (33.3%) were the most 
common ones. There was also no significant correla-
tion between HPV infection rate and the median age 
and gender of patients, which was in agreement with 
other studies (p > 0.05) [7].
It seems that HPV positive tumors have the ten-
dency to spread more rapidly than HPV-negative ones, 
but the survival of patients which are HPV-positive 
is better than HPV-negative patients [10]. This is pro-
bably because HPV positive tumors are more sensitive 
to chemotherapy [11]. Fakhry et al. implied that HPV 
positive cancers of head and neck may have 60 to 80% 
less mortality rate in comparison with HPV-negative 
patients [12]. In this study, the overall survival of pa-
tients with HPV negative tumors was worse than those 
with HPV-positive tumors (mortality rate of 37.5 versus 
0%) [12]. Ang et al. reported that three year survival 
is by 25% higher for HPV positive patients with oro-
pharyngeal cancers rather than ones without HPV 
in their tumors (82.4 against 57.1%) [13]. In our study, 
the mortality rates of HPV-negative and HPV-positive 
patients were 37.5 and 0%, respectively.
In conclusion, the presence of HPV and its sub-
types were investigated in NPC in the current study. 
In addition, it can be implied that patients which are 
HPV positive had better prognosis and also lesser 
recurrence. This study has a number of limitations; 
especially in quantity of cases for determining more 
precise correlation between the presence of HPV, 
prognosis and WHO typing. Further investigation may 
lead to a determination of the effect of HPV on the dis-
ease prognosis and could also provide some keys 
to the prevention and the treatment of NPC.
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